

## Prof. TANER DEMİRER

### Personal Information

Web: <https://avesis.ankara.edu.tr/demirer>

### International Researcher IDs

ORCID: 0000-0002-2214-5927

Publons / Web Of Science ResearcherID: AIB-5048-2022

ScopusID: 55393694800

Yoksis Researcher ID: 8812

### Education Information

Post Doctorate of Medicine, University of Washington, Kemik İliği Ve Kök Hücre Transplantasyonu İhtisası, United States Of America 1994 - 1996

Post Doctorate of Medicine, University of Washington, Hematoloji-Onkoloji İhtisası, United States Of America 1992 - 1995

Post Doctorate of Medicine, University of Wisconsin - Madison, İç Hastalıkları İhtisası, United States Of America 1989 - 1992

Post Doctorate of Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1978 - 1984

Undergraduate, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1978 - 1984

### Foreign Languages

English, C1 Advanced

### Research Areas

Health Sciences

### Academic Titles / Tasks

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 1997 - Continues

### Courses

HEMATOLOJİ, Undergraduate, 2013 - 2014, 2012 - 2013, 2011 - 2012, 2010 - 2011, 2009 - 2010, 2008 - 2009, 2007 - 2008, 2006 - 2007, 2005 - 2006, 2004 - 2005, 2003 - 2004, 2002 - 2003, 2001 - 2002, 2000 - 2001

### Advising Theses

DEMİRER T., Paroksizmal nokturnal hemoglobinüri hastalığında akım sitometrik ve klinik bulguların karşılaştırmalı değerlendirilmesi, Expertise In Medicine, S.BAŞLAR(Student), 2012

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center**  
CENGİZ SEVAL G., Civriz Bozdag S., TOPRAK S. K., Kurt Yuksel M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., Gurman G., BEKSAÇ M., İlhan O., et al.  
Balkan medical journal, vol.40, no.3, pp.197-204, 2023 (SCI-Expanded)
- II. **Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data**  
Kırcalı E., Cengiz Seval G., Öztürk C., Yılmaz H., Koyun D., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., Özcan M., et al.  
BALKAN MEDICAL JOURNAL, vol.40, no.1, pp.51-56, 2023 (SCI-Expanded)
- III. **Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia**  
Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., Yuksel M., Topcuoglu P., Arslan Ö., Demirer T., et al.  
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.22, no.8, pp.596-600, 2022 (SCI-Expanded)
- IV. **Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease**  
KOYUN D., CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., DEMİRER T., İLHAN O., et al.  
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.38, no.3, pp.601-605, 2022 (SCI-Expanded)
- V. **The efficacy and safety of second allogeneic hematopoietic stem cell transplantation.**  
Toprak S. K., Korcalo E., Seval G. C., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Gurman G., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- VI. **The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma**  
İlhan O., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., Arslan O., Özcan M., Demirer T., Gurman G., et al.  
BLOOD, vol.138, 2021 (SCI-Expanded)
- VII. **Prospective Follow-up of Panel Reactive Antibodies From Diagnosis Until Completion of Therapy Including Allogeneic Stem Cell Transplantation Among Patients With Acute Leukemia.**  
Sahin Eroglu D., Dalva K., Kalaci E., Toprak S. K., Civriz Bozdag S., Topcuoglu P., Demirer T., Gurman G., Yuksel M.  
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2021 (SCI-Expanded)
- VIII. **Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic**  
CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.6, pp.2799-2809, 2021 (SCI-Expanded)
- IX. **Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag**  
Kırcalı E., CENGİZ SEVAL G., KOYUN D., Ozturk C., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.410-411, 2020 (SCI-Expanded)
- X. **The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation**  
CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.204, 2020 (SCI-Expanded)
- XI. **Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)**

CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.192-193, 2020 (SCI-Expanded)

- XII. **Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?**

CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

BONE MARROW TRANSPLANTATION, vol.55, no.SUPPL 1, pp.305-306, 2020 (SCI-Expanded)

- XIII. **Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation**

Atilla P. A., AKKUŞ E., Atilla E., Gökmen İnan N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPRAK S. K., Baskal N., Akan H., DEMİRER T., et al.

CLINICAL TRANSPLANTATION, vol.34, no.10, 2020 (SCI-Expanded)

- XIV. **Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation**

Atilla P. A., Akkus E., Atilla E., Gokmen N., Bozdag S. C., TOPRAK S. K., Yuksel M. K., Ozcan M., Demirer T., Ilhan O., et al.

TRANSFUSION CLINIQUE ET BIOLOGIQUE, vol.27, no.3, pp.115-121, 2020 (SCI-Expanded)

- XV. **Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.**

Demirer T., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., Gurman G., Ilhan O., Beksac M., Özcan M.

JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15\_suppl, pp.19522, 2020 (SCI-Expanded)

- XVI. **Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data**

Seval G. C., Uslu A., Kircali E., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Dalva K., Arslan O., Ozcan M., et al. Transplantation and Cellular Therapy, vol.26, no.3, pp.305-306, 2020 (SCI-Expanded)

- XVII. **Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**

Seval G. C., Ozturk N., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Gurman G., Ilhan O., et al.

Transplantation and Cellular Therapy, vol.26, no.3, pp.109-110, 2020 (SCI-Expanded)

- XVIII. **An uncommon presentation of diffuse large B cell lymphoma with multiple peripheral nerve involvement demonstrated BY 18F-FDG PET/CT**

Araz M., Soydal Ç., Ozturk C., Özkan E., Demirer T.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.47, no.1, pp.218-219, 2020 (SCI-Expanded)

- XIX. **Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors**

Sahin U., DEMİRER T.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.50, pp.1697-1706, 2020 (SCI-Expanded)

- XX. **Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation**

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded)

- XXI. **Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?**

Ilhan O., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., Arslan O., Özcan M., Demirer T., Akan H., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.15\_suppl, pp.19524, 2019 (SCI-Expanded)

- XXII. **Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in**

**myeloma patients undergoing autologous stem cell transplantation.**

Demirer T., Cengiz Seval G., Toprak S. K., Civriz Bozdog S., Yuksel M. K., Topcuoglu P., Arslan O., Özcan M., Akan H., Ilhan O., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.37, no.15\_suppl, pp.19532, 2019 (SCI-Expanded)

- XXIII. **Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)**  
Seval G. C., Atilla E., Ulas B., Bozdog S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., et al.  
Transplantation and Cellular Therapy, vol.25, no.3, pp.176-177, 2019 (SCI-Expanded)
- XXIV. **Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients**  
Atilla E., Topcuoglu P., Akkus E., Atilla P. A., Bozdog S. C., Yuksel M. K., Demirer T., Arslan O., Ozcan M., Ilhan O., et al.  
Transplantation and Cellular Therapy, vol.25, no.3, pp.322, 2019 (SCI-Expanded)
- XXV. **Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation**  
Atilla E., Atilla P. A., CENGİZ SEVAL G., Bektas M., DEMİRER T.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.2, pp.122-131, 2019 (SCI-Expanded)
- XXVI. **Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma**  
Uckun F. M., Qazi S., DEMİRER T., Champlin R. E.  
EBIOMEDICINE, vol.39, pp.612-620, 2019 (SCI-Expanded)
- XXVII. **Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience**  
Topcuoglu P., Cengiz Seval G., Civriz Bozdog S., Toprak S. K., Kurt Yuksel M., Dalva K., Arslan O., Özcan M., Demirer T., Ilhan O., et al.  
BLOOD, vol.132, no.Supplement 1, pp.5776, 2018 (SCI-Expanded)
- XXVIII. **Is there a role of high dose chemotherapy and autologous stem cell transplantation in the treatment of Ewing's sarcoma and osteosarcomas?**  
Karadurmus N., Sahin U., Basgoz B. B., DEMİRER T.  
JOURNAL OF BUON, vol.23, no.5, pp.1235-1241, 2018 (SCI-Expanded)
- XXIX. **Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma**  
Sahin U., DEMİRER T.  
JOURNAL OF CLINICAL APHERESIS, vol.33, no.3, pp.357-370, 2018 (SCI-Expanded)
- XXX. **Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.**  
CENGİZ SEVAL G., Bulat B., Ozel F., Tasci O., KUZU I., CİVRİZ BOZDAĞ S., Toprak S. K., YÜKSEL M., Topcuoglu P., Ozcan M., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XXXI. **Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma**  
Ilhan O., Seval G. C., Toprak S. K., Bozdog S. C., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Akan H., et al.  
Transplantation and Cellular Therapy, vol.24, no.3, pp.142, 2018 (SCI-Expanded)
- XXXII. **Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation**  
CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.  
BALKAN MEDICAL JOURNAL, vol.35, no.2, pp.131-140, 2018 (SCI-Expanded)
- XXXIII. **Adult Stem Cells and Medicine**  
CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T.  
CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 1: STEM CELLS IN REGENERATIVE MEDICINE: ADVANCES

AND CHALLENGES, vol.1079, pp.17-36, 2018 (SCI-Expanded)

**XXXIV. Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?**

Atilla E., Yalciner M., Ailla P. A., Ates C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Gunduz M., Ozen M., Akan H., et al.

ANTIVIRAL THERAPY, vol.23, no.8, pp.647-653, 2018 (SCI-Expanded)

**XXXV. Extracorporeal photochemotherapy in mycosis fungoides**

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Topcuoglu P., Akay B. N., Sanli H., Akan H., Demirer T., et al.

TRANSFUSION CLINIQUE ET BIOLOGIQUE, vol.24, no.4, pp.454-457, 2017 (SCI-Expanded)

**XXXVI. A review of late complications of allogeneic hematopoietic stem cell transplantations**

Atilla E., Atilla P. A., TOPRAK S. K., DEMİRER T.

CLINICAL TRANSPLANTATION, vol.31, no.10, 2017 (SCI-Expanded)

**XXXVII. A review of infectious complications after haploidentical hematopoietic stem cell transplantations**

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., DEMİRER T.

INFECTION, vol.45, no.4, pp.403-411, 2017 (SCI-Expanded)

**XXXVIII. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation**

Gunduz M., Ozen M., Sahin U., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., BEKSAÇ M., et al.

CLINICAL TRANSPLANTATION, vol.31, no.7, 2017 (SCI-Expanded)

**XXXIX. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?**

Atilla P. A., Ozturk S. M. B., DEMİRER T.

TRANSFUSION AND APHERESIS SCIENCE, vol.56, no.2, pp.190-198, 2017 (SCI-Expanded)

**XL. Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients**

GÜRMAN G., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol.23, no.3, 2017 (SCI-Expanded)

**XLI. An overview of high dose chemotherapy with autologous stem cell rescue for germ cell tumors in current practice**

Ozaydin S., Sahin U., Karadurmus N., Arpacı F., DEMİRER T.

JOURNAL OF BUON, vol.22, no.2, pp.306-311, 2017 (SCI-Expanded)

**XLII. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?**

Atilla E., Atilla P. A., DEMİRER T.

INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.105, no.3, pp.257-264, 2017 (SCI-Expanded)

**XLIII. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study**

Ozen M., Ustun C., Ozturk B., TOPÇUOĞLU P., Arat M., Gunduz M., Atilla E., Bolat G., ARSLAN Ö., DEMİRER T., et al.

TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.16-26, 2017 (SCI-Expanded)

**XLIV. Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation**

Atilla E., TOPRAK S. K., DEMİRER T.

TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.1-9, 2017 (SCI-Expanded)

**XLV. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations**

Atilla E., Atilla P. A., DEMİRER T.

BALKAN MEDICAL JOURNAL, vol.34, no.1, pp.1-9, 2017 (SCI-Expanded)

**XLVI. Iron Overload in Hematopoietic Stem Cell Transplantation Reply**

Atilla E., TOPRAK S. K., Demirer T.

TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.103, 2017 (SCI-Expanded)

**XLVII. Re: Iron overload in hematopoietic stem cell transplantation Re: Hematopoetik kök hücre**

**transplantasyonunda aşırı demir yüklenmesi**

Atilla E., TOPRAK S. K., DEMİRER T.

Turkish Journal of Hematology, vol.34, no.1, pp.103, 2017 (SCI-Expanded)

**XLVIII. Therapeutic Plasma Exchange for Thrombotic Microangiopathy**

Ilhan O., Atilla E., Ataca Atilla P., Civriz Bozdag S., Kurt Yuksel M., Toprak S. K., Topcuoglu P., Akan H., Demirer T., Beksac M., et al.

BLOOD, vol.128, no.22, pp.4939, 2016 (SCI-Expanded)

**XLIX. An overview of hematopoietic stem cell transplantation related thrombotic complications**

Sahin U., Atilla P. A., Atilla E., TOPRAK S. K., DEMİRER T.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.107, pp.149-155, 2016 (SCI-Expanded)

**L. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation**

Sahin U., TOPRAK S. K., Atilla P. A., Atilla E., DEMİRER T.

JOURNAL OF INFECTION AND CHEMOTHERAPY, vol.22, no.7-8, pp.505-514, 2016 (SCI-Expanded)

**LI. High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Breast Cancer: Is There Still a Hope?**

DEMİRER T.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.182-187, 2016 (SCI-Expanded)

**LII. Non-Infectious Early Complications of Allogeneic Stem Cell Transplantations**

Atilla P. A., Atilla E., TOPRAK S. K., DEMİRER T.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.4, pp.239-250, 2016 (SCI-Expanded)

**LIII. A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction**

Ozen M., Yilmaz G., Coskun B., TOPÇUOĞLU P., Ozturk B., Gunduz M., Atilla E., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.1, pp.41-47, 2016 (SCI-Expanded)

**LIV. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation**

Merter M., Atilla E., Sahin U., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Gurman G., et al.

BLOOD, vol.126, no.23, pp.5456, 2015 (SCI-Expanded)

**LV. Is Initial CD3+ T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?**

Atilla E., Ataca P., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Ilhan O., Beksac M., et al.

BLOOD, vol.126, no.23, pp.5483, 2015 (SCI-Expanded)

**LVI. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients**

Gurman G., Ataca P., Atilla E., Civriz Bozdag S., Toprak S. K., Yuksel M. K., Demirer T., Akan H., Arslan O., Topcuoglu P., et al.

BLOOD, vol.126, no.23, pp.1952, 2015 (SCI-Expanded)

**LVII. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation**

Martino M., Lanza F., DEMİRER T., Moscato T., Secondino S., Pedrazzoli P.

EXPERT OPINION ON BIOLOGICAL THERAPY, vol.15, no.2, pp.195-211, 2015 (SCI-Expanded)

**LVIII. Antilymphocyte/Thymocyte Globulin for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: 20-Year Experience at a Single Center**

Ozen M., CİVRİZ BOZDAĞ S., Cakmak G., TOPÇUOĞLU P., Eroglu A. H., Glunduz M., ARSLAN Ö., DEMİRER T., Akan H., İLHAN O., et al.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.25, no.4, pp.236-244, 2015 (SCI-Expanded)

**LIX. Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients**

Topcuoglu P., Ataca P., Bozdag S. C., Toprak S. K., Arslan O., Ozcan M., Demirer T., Konuk N., Akan H., Ilhan O., et al.

BLOOD, vol.124, no.21, pp.5887, 2014 (SCI-Expanded)

- LX. **Do FMS-like Tyrosine Kinase 3 and Nucleophosmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?**  
Gunduz M., Ataca P., Ozen M., Atilla E., Bozdag S. C., Toprak S. K., Topcuoglu P., Ozcan M., Demirer T., Beksac M., et al.  
BLOOD, vol.124, no.21, pp.5328, 2014 (SCI-Expanded)
- LXI. **Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?**  
Ilhan O., Ataca P., Atilla E., Toprak S. K., Kaygusuz G., Kuzu I., Bozdag S. C., Topcuoglu P., Arslan O., Ozcan M., et al.  
BLOOD, vol.124, no.21, pp.5555, 2014 (SCI-Expanded)
- LXII. **Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation**  
Topcuoglu P., Gunduz M., Ozen M., Civriz Bozdag S., Kocak Toprak S., Arslan O., Ozcan M., Demirer T., Ilhan O., Akan H., et al.  
BLOOD, vol.124, no.21, pp.5891, 2014 (SCI-Expanded)
- LXIII. **Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience**  
Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., Pekcan G., Merter M., Gunduz M., Ozen M., et al.  
BLOOD, vol.124, no.21, pp.5448, 2014 (SCI-Expanded)
- LXIV. **Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center**  
Sahin U., Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., Civriz Bozdag S., Toprak S. K., Topcuoglu P., Arslan O., et al.  
BLOOD, vol.124, no.21, pp.5150, 2014 (SCI-Expanded)
- LXV. **Response to: 'Are there still reasons to believe that high-dose chemotherapy plays a role in breast cancer management?'**  
DEMİRER T.  
Bone Marrow Transplantation, vol.48, no.2, pp.306, 2013 (SCI-Expanded)
- LXVI. **Novel agents and approaches for stem cell mobilization in normal donors and patients**  
Bakanay Ş., DEMİRER T.  
Bone Marrow Transplantation, vol.47, no.9, pp.1154-1163, 2012 (SCI-Expanded)
- LXVII. **High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials**  
Berry D. A., Ueno N. T., Johnson M. M., Lei X., Caputo J., Smith D. A., Yancey L. J., Crump M., Stadtmauer E. A., Biron P., et al.  
Journal of Clinical Oncology, vol.29, no.24, pp.3224-3231, 2011 (SCI-Expanded)
- LXVIII. **High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials**  
Berry D. A., Ueno N. T., Johnson M. M., Lei X., Caputo J., Rodenhuis S., Peters W. P., Leonard R. C., Barlow W. E., Tallman M. S., et al.  
Journal of Clinical Oncology, vol.29, no.24, pp.3214-3223, 2011 (SCI-Expanded)
- LXIX. **Allogeneic hematopoietic stem cell transplantation in ovarian cancer - The EBMT experience**  
Bay J., Cabrespine-Faugeras A., Tabrizi R., Blaise D., Viens P., Ehninger G., Bornhauser M., Slavin S., Rosti G., Peccatori J., et al.  
International Journal of Cancer, vol.127, no.6, pp.1446-1452, 2010 (SCI-Expanded)
- LXX. **Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF**  
Ozcelik T., Topcuoglu P., BEKSAÇ M., Ozcan M., Arat M., Biyikli Z., Bakanay S. M., İlhan O., GÜRMAN G., Arslan O., et al.  
BONE MARROW TRANSPLANTATION, vol.44, no.12, pp.779-783, 2009 (SCI-Expanded)
- LXXI. **Severe Henoch-Schonlein Purpura Induced by Cytarabine**  
Aktas B., TOPÇUOĞLU P., Kurt O. K., ENSARİ A., Demirer T.  
ANNALS OF PHARMACOTHERAPY, vol.43, no.4, pp.792-793, 2009 (SCI-Expanded)
- LXXII. **Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience**

- Aglietta M., Barkholt L., Schianca F. C., Caravelli D., Omazic B., Minotto C., Leone F., Hentschke P., Bertoldero G., Capaldi A., et al.  
Biology of Blood and Marrow Transplantation, vol.15, no.3, pp.326-335, 2009 (SCI-Expanded)
- LXXIII. **Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience**  
İLHAN O., TOPÇUOĞLU P., Arat M., Soydan E. A., YÜKSEL M., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., Akan H., et al.  
Turkish Journal of Hematology, vol.25, no.2, pp.87-93, 2008 (SCI-Expanded)
- LXXIV. **28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures**  
Ladenstein R., Poetschger U., Hartman O., Pearson A. D. J., Klingebiel T., Castel V., Yaniv I., Demirer T., Dini G.  
BONE MARROW TRANSPLANTATION, vol.41, 2008 (SCI-Expanded)
- LXXV. **Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors**  
DEMİRER T., Barkholt L., Blaise D., Pedrazzoli P., Aglietta M., Carella A. M., Bay J., Arpacı F., Rosti G., GÜRMAN G., et al.  
NATURE CLINICAL PRACTICE ONCOLOGY, vol.5, no.5, pp.256-267, 2008 (SCI-Expanded)
- LXXVI. **Allogeneic hematopoietic cell transplantation for metastatic breast cancer**  
Ueno N. T., Rizzo J. D., Demirer T., Cheng Y. C., Hegenbart U., Zhang M., Bregni M., Carella A., Blaise D., Bashey A., et al.  
BONE MARROW TRANSPLANTATION, vol.41, no.6, pp.537-545, 2008 (SCI-Expanded)
- LXXVII. **High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: The experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party**  
De Giorgi U., Blaise D., Lange A., Viens P., Marangolo M., Madroszyk A., Brune M., Afanassiev B. V., Rosti G., Demirer T.  
BONE MARROW TRANSPLANTATION, vol.40, no.11, pp.1045-1048, 2007 (SCI-Expanded)
- LXXVIII. **High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults**  
Pedrazzoli P., Rosti G., Secondino S., Carminati O., Demirer T.  
SEMINARS IN HEMATOLOGY, vol.44, no.4, pp.286-295, 2007 (SCI-Expanded)
- LXXIX. **Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation**  
Secondino S., Carrabba M. G., Pedrazzoli P., Castagna L., Spina F., Grosso F., Bertuzzi A., Bay J., Siena S., Corradini P., et al.  
HAEMATOLOGICA, vol.92, no.3, pp.418-420, 2007 (SCI-Expanded)
- LXXX. **High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults**  
Pedrazzoli P., Ledermann J. A., Lotz J. -, Leyvraz S., Aglietta M., Rosti G., Champion K. M., Secondino S., Selle F., Ketterer N., et al.  
ANNALS OF ONCOLOGY, vol.17, no.10, pp.1479-1488, 2006 (SCI-Expanded)
- LXXXI. **Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe**  
Barkholt L., Bregni M., Remberger M., Blaise D., Peccatori J., Massenkeil G., Pedrazzoli P., Zambelli A., Bay J. -, Francois S., et al.  
ANNALS OF ONCOLOGY, vol.17, no.7, pp.1134-1140, 2006 (SCI-Expanded)
- LXXXII. **Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe**  
Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M., Demirer T., Dini G., Einsele H., Gratwohl A., Madrigal A., Niederwieser D., Passweg J., et al.  
BONE MARROW TRANSPLANTATION, vol.37, no.5, pp.439-449, 2006 (SCI-Expanded)
- LXXXIII. **Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation**



- Peccatori J., Barkholt L., Demirer T., Sormani M., Bruzzi P., Ciceri F., Zambelli A., Da Prada G., Pedrazzoli P., Siena S., et al.  
CANCER, vol.104, no.10, pp.2099-2103, 2005 (SCI-Expanded)
- LXXXIV. **Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours**  
De Giorgi U., Rosti G., Slavin S., Yaniv I., Harousseau J., Ladenstein R., Demirer T., Dini G.  
BRITISH JOURNAL OF CANCER, vol.93, no.4, pp.412-417, 2005 (SCI-Expanded)
- LXXXV. **High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)**  
Bengala C., Guarneri V., Ledermann J., Rosti G., Wandt H., Lotz J., Cure J., Orlandini C., Ferrante P., Conte P., et al.  
BONE MARROW TRANSPLANTATION, vol.36, no.1, pp.25-31, 2005 (SCI-Expanded)
- LXXXVI. **Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience**  
De Giorgi U., Demirer T., Wandt H., Taverna C., Siegert W., Bornhauser M., Kozak T., Papiani G., Ballardini M., Rosti G.  
ANNALS OF ONCOLOGY, vol.16, no.1, pp.146-151, 2005 (SCI-Expanded)
- LXXXVII. **First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party**  
Rosti G., De Giorgi U., Wandt H., Lioure B., Leyvraz S., Kolbe K., Papiani G., Ballardini M., Kulekci A., Demirer T.  
BONE MARROW TRANSPLANTATION, vol.34, no.12, pp.1033-1037, 2004 (SCI-Expanded)
- LXXXVIII. **High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - A retrospective evaluation**  
Demirer T., Ayli M., Fen T., Ozcan M., Arat M., Buyukberber S., Arslan O., GÜRMAN G., Akan H., Ilhan O.  
Bone Marrow Transplantation, vol.34, no.9, pp.781-786, 2004 (SCI-Expanded)
- LXXXIX. **The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.**  
Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., Gurman G., Demirer T., Akan H., Beksac M., et al.  
BLOOD, vol.104, no.11, pp.5146, 2004 (SCI-Expanded)
- XC. **Allogeneic Hemapoietic Progenitor Cell Collection Using Four Different Cell Separators: A Retrospective Comparative Analysis.**  
Arat M., Arslan O., Soydan E. A., Ayyildiz E., Dalva K., Tol M., Ozcan M., Gürman G., Demirer T., Akan H., et al.  
BLOOD, vol.104, no.11, pp.5009, 2004 (SCI-Expanded)
- XCI. **Hematopoetic stem cell transplantation for solid tumors in Europe**  
Gratwohl A., Baldomero H., Demirer T., Rosti G., Dini G., Ladenstein R., Urbano-Ispizua A.  
ANNALS OF ONCOLOGY, vol.15, no.4, pp.653-660, 2004 (SCI-Expanded)
- XCII. **Second-line high-dose chemotherapy in patients with extragonadial nonseminomatous germ cell tumors: the experience of the European Group for Blood and Marrow Transplantation (EBMT)**  
De Giorgi U., DEMİRER T., Wandt H., Taverna C., Siegert W., Borhauser M., Kozak T., Papiani G., Ballardini M., Rosti G.  
ANNALS OF ONCOLOGY, vol.15, pp.121, 2004 (SCI-Expanded)
- XCIII. **Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients**  
Kroger N., Damon L., Zander A., Wandt H., Derigs G., Ferrante P., Demirer T., Rost G.  
BONE MARROW TRANSPLANTATION, vol.32, no.12, pp.1153-1157, 2003 (SCI-Expanded)
- XCIV. **Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999**  
Pedrazzoli P., Ferrante P., Kulekci A., Schiavo R., De Giorgi U., Carminati O., Marangolo M., Demirer T., Siena S., Rosti G.  
BONE MARROW TRANSPLANTATION, vol.32, no.5, pp.489-494, 2003 (SCI-Expanded)
- XC. **High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation**  
Demirer T., Uysal V., Ayli M., Genc Y., Ilhan O., Koc H., Dagli M., Arat M., Gunel N., Fen T., et al.

BONE MARROW TRANSPLANTATION, vol.31, no.9, pp.755-761, 2003 (SCI-Expanded)

- XCVI. **Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation**  
Kroger N, Zander A, Martinelli G, Ferrante P, Moraleda J, Da Prada G, Demirer T, Socie G, Rosti G.  
ANNALS OF ONCOLOGY, vol.14, no.4, pp.554-558, 2003 (SCI-Expanded)
- XCVII. **CD34+ cells in hematopoietic stem cell transplantation**  
Demirer T.  
TISSUE ENGINEERING, STEM CELLS AND GENE THERAPIES, vol.534, pp.107-118, 2003 (SCI-Expanded)
- XCVIII. **The role of ABO incompatibility in allogeneic peripheral blood stem cell transplantation**  
ARSLAN Ö, Coşkun H. Ş., Arat M., Soydan E., ÖZCAN M., GÜRMAN G., Çelebi H., DEMİRER T., Akan H., İLHAN O., et al.  
Turkish Journal of Haematology, vol.19, no.3, pp.401-409, 2002 (SCI-Expanded)
- XCIX. **The effect of post-transplant spironolactone on daily potassium requirements in patients undergoing autologous stem cell transplantation**  
Demirer T., Ayli M., Dagli M., Fen T., Haznedar R., Ustael N., Ustun T., Oymak A., Ozdel O., Muftuoglu O.  
BONE MARROW TRANSPLANTATION, vol.30, no.10, pp.703-704, 2002 (SCI-Expanded)
- C. **Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield**  
Demirer T., İlhan O., Ayli M., Arat M., Dagli M., Ozcan M., Haznedar R., Genc Y., Fen T., Ayyildiz E., et al.  
THERAPEUTIC APHERESIS, vol.6, no.5, pp.384-389, 2002 (SCI-Expanded)
- CI. **Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation.**  
Demirer T., Ayli M., Dagli M., Haznedar R., Genc Y., Fen T., Dincer S., Unal E., Gunel N., Seyrek E., et al.  
British journal of haematology, vol.118, no.4, pp.1104-11, 2002 (SCI-Expanded)
- CII. **A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters**  
Demirer T., Dagli M., İlhan O., Ayli M., Haznedar R., Fen T., Gunel N., Genc Y., Arat M., Ozcan M., et al.  
BONE MARROW TRANSPLANTATION, vol.29, no.11, pp.893-897, 2002 (SCI-Expanded)
- CIII. **Does donor recipient ABO-incompatibility have any effect on the course and outcome of allogeneic hematopoietic cell transplantation?**  
Arslan O., Arat M., Soydan E., COŞKUN H. Ş., Topcuoglu P., Ozcan M., GÜRMAN G., Demirer T., İlhan O., Koc H., et al.  
BONE MARROW TRANSPLANTATION, vol.29, 2002 (SCI-Expanded)
- CIV. **Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF**  
Demirer T., Ayli M., Ozcan M., Gunel N., Haznedar R., Dagli M., Fen T., Genc Y., Dincer S., Arslan O., et al.  
BRITISH JOURNAL OF HAEMATOLOGY, vol.116, no.2, pp.468-474, 2002 (SCI-Expanded)
- CV. **Plasmacytoma in the bilateral breast**  
Dağlı M., DEMİRER T., Ayli M., Haznedar R., GÜNEL N., Sucak G., Fen T., Moran M., Üstün T., Aybirdi C., et al.  
Turkish Journal of Haematology, vol.19, no.4, pp.481-483, 2002 (SCI-Expanded)
- CVI. **An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration.**  
Arat M., Ulusoy V., Demirer T., Uysal A., Ozcan M., Dincer S., İlhan O., Koc H.  
Leukemia & lymphoma, vol.43, no.1, pp.145-8, 2002 (SCI-Expanded)
- CVII. **Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony stimulating factor (rh-GSCF): A randomized evaluation of different doses of rh-G-CSF.**  
Demirer T., Ayli M., Arat M., Ozcan M., Gunel N., Haznedar R., Dagli M., Arslan O., GÜRMAN G., Demirer S., et al.  
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)
- CVIII. **A randomized trial of assessment of efficacy of leukapheresis volumes, 8 L versus 10L.**  
Demirer T., Ayli M., Arat M., Gunel N., Ozcan M., Haznedar R., Arslan O., GÜRMAN G., Dagli M., Fen T., et al.  
BLOOD, vol.98, no.11, 2001 (SCI-Expanded)
- CIX. **CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic**

**peripheral blood stem cell transplantation**

DEMİRER T., İlhan O., Arat M., YAVUZ Y., ÖZCAN M. E., DALVA K., ÇELEBİ H., Beksaç M., Akan H., Gürman G., et al.  
Journal of Clinical Apheresis, vol.16, no.2, pp.67-73, 2001 (SCI-Expanded)

- CX. **High-dose Thiotepa, Melphalan and Carboplatin (TMCB) with autologous Peripheral Blood Stem Cell (PBSC) support in patients with hematologic malignancies and solid tumors**  
Demirer T., İlhan O., Ayli M., Arat M., Fen T., Ozcan M., Arslan O., GÜRMAN G., Akan H., Konuk N., et al.  
BONE MARROW TRANSPLANTATION, vol.27, 2001 (SCI-Expanded)
- CXI. **Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation**  
Ozcan M., Ustun C., Akcaglayan E., Akan H., Arslan O., İlhan O., BEKSAÇ M., GÜRMAN G., Demirer T., Arat M., et al.  
BONE MARROW TRANSPLANTATION, vol.27, no.5, pp.499-505, 2001 (SCI-Expanded)
- CXII. **CD41+and CD42+hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation**  
Demirer T., İlhan O., Arat M., Genc Y., Ozcan M., Dalva K., Celebi H., BEKSAÇ M., Akan H., GÜRMAN G., et al.  
JOURNAL OF CLINICAL APHERESIS, vol.16, no.2, pp.67-73, 2001 (SCI-Expanded)
- CXIII. **The value of peripheral blood CD34(+) cell quantification in autologous hematopoietic stem cell apheresis.**  
İlhan O., Arslan O., Arat M., Ozcan M., GÜRMAN G., Dalva K., BEKSAÇ M., Demirer T., Konuk N., Uysal A., et al.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CXIV. **Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), epirubicin and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast and ovarian cancer.**  
Demirer T., Ayli M., Demirer A., Ulusoy V., Fen T., Celik Z., Oymak A., Ozdel O., Ustael N., Ustun T.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CXV. **Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors.**  
Demirer T., İlhan O., Ayli M., Arat M., Fen T., Haznedar R., Ozcan M., Arslan O., GÜRMAN G., Akan H., et al.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CXVI. **Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), etoposide and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with hematologic malignancies and solid tumors.**  
Demirer T., Ayli M., Demirer A., Fen T., Haznedar R., Celik Z., Oymak A., Ozdel O., Ustael N., Ustun T., et al.  
BLOOD, vol.96, no.11, 2000 (SCI-Expanded)
- CXVII. **Comparison of the efficacy of medium chain triglycerides with long chain triglycerides in total parenteral nutrition in patients with hematologic malignancies undergoing peripheral blood stem cell transplantation**  
Demirer S., Aydintug S., Ustun C., Turkmen E., Tuzun A., Simsek S., Basaran O., Celebi H., Demirer T.  
CLINICAL NUTRITION, vol.19, no.4, pp.253-258, 2000 (SCI-Expanded)
- CXVIII. **Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of İbni Sina Hospital**  
Arslan O., COŞKUN H. Ş., Arat M., Celebi H., Ozcan M., GÜRMAN G., Ustun C., Demirer T., Akan H., İlhan O., et al.  
BONE MARROW TRANSPLANTATION, vol.25, no.12, pp.1229-1232, 2000 (SCI-Expanded)
- CXIX. **A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBST) in patients with solid tumors and hematologic malignancies**  
Demirer T., İlhan O., Mandel N., Arat M., Gunel N., Celebi H., Ustun C., Akan H., Demirer S., Aydintug S., et al.  
BONE MARROW TRANSPLANTATION, vol.25, no.7, pp.697-703, 2000 (SCI-Expanded)
- CXX. **Primary low-grade lymphomas of the intestine - Case 1: Immunoproliferative small intestinal disease**  
Demirer T., Celebi H., Akcaglayan E., Ustun C., Demirer S., Ekinci C., Bahar K., Koc H.  
JOURNAL OF CLINICAL ONCOLOGY, vol.17, no.11, pp.3682-3684, 1999 (SCI-Expanded)
- CXXI. **Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood**

**stem cell transplantation: A case report**

Üstün C., Çelebi H., Arat M., ÖZCAN M., Dilek I., GÜRMAN G., DEMİRER T., İLHAN O., Keskin R., Koç H.  
Therapeutic Apheresis, vol.3, no.3, pp.275-277, 1999 (SCI-Expanded)

- CXXII. **Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation**  
Demirer T., Celebi H., Arat M., Ustun C., Demirer S., Dilek I., Ozcan M., Ilhan O., Akan H., GÜRMAN G., et al.  
BONE MARROW TRANSPLANTATION, vol.24, no.3, pp.335-337, 1999 (SCI-Expanded)
- CXXIII. **Peripheral blood stem cell mobilization for high-dose chemotherapy**  
Demirer T., Bensinger W., Buckner C.  
JOURNAL OF HEMATOTHERAPY, vol.8, no.2, pp.103-113, 1999 (SCI-Expanded)
- CXXIV. **Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.**  
Ustun C., Ozcan M., Beksac M., Ilhan O., Cakir M., GÜRMAN G., Arslan O., Akan H., Demirer T., Arat M., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CXXV. **Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.**  
GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., Celebi H., Ozcan M., Ilhan O., Demirer T., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CXXVI. **A protocol proposal comparing conventional approach with high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in patients with small cell lung cancer limited to thorax.**  
Demirer T., Arat M., Koc H., Ilhan O., Celebi H., Ozcan M., Akan H., GÜRMAN G., Uysal A.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CXXVII. **Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY) - Paclitaxel and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast cancer: İbni Sina experience**  
Arat M., Demirer T., Ilhan O., Koc H., Ustun C., Celebi H., Ayyildiz E., Tuziin A., Gunman G., Ozcan M.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CXXVIII. **The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.**  
Ozcan M., Ustun C., Ilhan O., Beksac M., Akcaglayan E., GÜRMAN G., Akan H., Demirer T., Arat M., Celebi H., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CXXIX. **The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.**  
Ilhan O., Demirer T., Arat M., Dalva K., COŞKUN H. Ş., BEKSAÇ M., Akan H., Ozcan M., Arslan O., GÜRMAN G., et al.  
BONE MARROW TRANSPLANTATION, vol.23, 1999 (SCI-Expanded)
- CXXX. **Differences in liver pathology and clinical outcome between two patients with Hepatitis B virus and graft versus host disease**  
Üstün C., ÖZCAN M., GÜRMAN G., Çakir M., Erekuş S., AKYOL G., Arat M., Çelebi H., İdlman R., İLHAN O., et al.  
Pathology and Oncology Research, vol.5, no.3, pp.229-232, 1999 (SCI-Expanded)
- CXXXI. **A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse**  
Üstün C., ARSLAN Ö., BEKSAÇ M., Koç H., GÜRMAN G., Özçelik T., Yılmaz B., İlhan O., Akan H., ÖZCAN M., et al.  
Biology of Blood and Marrow Transplantation, vol.5, no.1, pp.28-35, 1999 (SCI-Expanded)
- CXXXII. **The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.**  
Ozcan M., Ustun C., Ilhan O., BEKSAÇ M., Akcaglayan E., GÜRMAN G., Akan H., Demirer T., Arat M., Celebi H., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CXXXIII. **Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.**  
Ustun C., Ozcan M., BEKSAÇ M., Ilhan O., Cakir M., GÜRMAN G., Akan H., Demirer T., Arat M., Celebi H., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)

- CXXXIV. **Allogeneic hematopoietic stem cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.**  
GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., Celebi H., Ozcan M., Ilhan O., Demirer T., et al.  
BLOOD, vol.92, no.10, 1998 (SCI-Expanded)
- CXXXV. **Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.**  
Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., Ilhan O., BEKSAÇ M., Uysal A., Konuk N., et al.  
HEPATOLOGY, vol.28, no.4, 1998 (SCI-Expanded)
- CXXXVI. **Acute myeloblastic leukemia associated with hyperleukocytosis and diabetes insipidus**  
Dilek I., Uysal A., Demirer T., Koc H., Ozcan M., Keles H., Numanoglu N., Ustun C., Ciftci E.  
LEUKEMIA & LYMPHOMA, vol.30, no.5-6, pp.657-660, 1998 (SCI-Expanded)
- CXXXVII. **Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia**  
Dilek I., Demirer T., Ustun C., Arat M., Koc H., BEKSAÇ M., Erdi H., Anadolu R., Ozcan M., Ilhan O., et al.  
BONE MARROW TRANSPLANTATION, vol.21, no.11, pp.1159-1161, 1998 (SCI-Expanded)
- CXXXVIII. **Tempo of hematologic recovery correlates with peripheral blood CD34+ cell level in patients undergoing stem cell mobilization**  
Williams O., DEMİRER T., Lilleby K., Buckner C. D., Bensinger W.  
Journal of Clinical Apheresis, vol.13, no.1, pp.1-6, 1998 (SCI-Expanded)
- CXXXIX. **High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer**  
Holmberg L., Demirer T., Rowley S., Buckner C., Goodman G., Maziarz R., Klarnet J., Zuckerman N., Harrer G., McCloskey R., et al.  
BONE MARROW TRANSPLANTATION, vol.22, no.7, pp.651-659, 1998 (SCI-Expanded)
- CXL. **Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor**  
Demirer T., Buckner C., Storer B., Lilleby K., Rowley S., Clift R., Appelbaum F., Storb R., Bensinger W.  
JOURNAL OF CLINICAL ONCOLOGY, vol.15, no.2, pp.684-690, 1997 (SCI-Expanded)
- CXLI. **Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation**  
Bensinger W., Clift R., Martin P., Appelbaum F., Demirer T., Gooley T., Lilleby K., Rowley S., Sanders J., Storb R., et al.  
BLOOD, vol.88, no.7, pp.2794-2800, 1996 (SCI-Expanded)
- CXLII. **Syngeneic marrow transplantation in patients with multiple myeloma**  
Bensinger W., DEMİRER T., Buckner C., Appelbaum F., Storb R., Lilleby K., Weiden P., Bluming A., Fefer A.  
Bone Marrow Transplantation, vol.18, no.3, pp.527-531, 1996 (SCI-Expanded)
- CXLIII. **Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia**  
DEMİRER T., Petersen F., Bensinger W., Appelbaum F., Fefer A., Rowley S., Sanders J., Chauncey T., Storb R., Lilleby K., et al.  
Bone Marrow Transplantation, vol.18, no.1, pp.29-34, 1996 (SCI-Expanded)
- CXLIV. **High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow and peripheral blood stem cells**  
Brunvand M., Bensinger W., Soll E., Weaver C., Rowley S., Appelbaum F., Lilleby K., Clift R., Gooley T., Press O., et al.  
Bone Marrow Transplantation, vol.18, no.1, pp.131-141, 1996 (SCI-Expanded)
- CXLV. **Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease**  
Schiffman K., Bensinger W., Appelbaum F., Rowley S., Lilleby K., Clift R., Weaver C., DEMİRER T., Sanders J., Petersdorf S., et al.  
Bone Marrow Transplantation, vol.17, no.6, pp.943-950, 1996 (SCI-Expanded)
- CXLVI. **Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma**  
DEMİRER T., Buckner C., Gooley T., Appelbaum F., Rowley S., Chauncey T., Lilleby K., Storb R., Bensinger W.

- Bone Marrow Transplantation, vol.17, no.6, pp.937-941, 1996 (SCI-Expanded)
- CXLVII. **High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer**  
DEMİRER T., Buckner C., Appelbaum F., Clift R., Storb R., Myerson D., Lilleby K., Rowley S., Bensinger W.  
Bone Marrow Transplantation, vol.17, no.5, pp.769-774, 1996 (SCI-Expanded)
- CXLVIII. **Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels**  
DEMİRER T., Buckner C., Appelbaum F., Bensinger W., Sanders J., Lambert K., Clift R., Fefer A., Storb R., Slattery J.  
Bone Marrow Transplantation, vol.17, no.4, pp.491-495, 1996 (SCI-Expanded)
- CXLIX. **Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels**  
DEMİRER T., Buckner C., Appelbaum F., Lambert K., Bensinger W., Clift R., Storb R., Slattery J.  
Bone Marrow Transplantation, vol.17, no.3, pp.341-346, 1996 (SCI-Expanded)
- CL. **High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma**  
Bensinger W., Rowley S., Demirer T., Lilleby K., Schiffman K., Clift R., Appelbaum F., Fefer A., Barnett T., Storb R., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.14, no.5, pp.1447-1456, 1996 (SCI-Expanded)
- CLI. **Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor**  
Bensinger W., Clift R., Anasetti C., Appelbaum F., Demirer T., Rowley S., Sandmaier B., TorokStorb B., Storb R., Buckner C.  
STEM CELLS, vol.14, no.1, pp.90-105, 1996 (SCI-Expanded)
- CLII. **Optimization of peripheral blood stem cell mobilization**  
Demirer T., Buckner C., Bensinger W.  
STEM CELLS, vol.14, no.1, pp.106-116, 1996 (SCI-Expanded)
- CLIII. **ALLOGENEIC MARROW TRANSPLANTATION FOLLOWING CYCLOPHOSPHAMIDE AND ESCALATING DOSES OF HYPERFRACTIONATED TOTAL-BODY IRRADIATION IN PATIENTS WITH ADVANCED LYMPHOID MALIGNANCIES - A PHASE I/II TRIAL**  
DEMİRER T., PETERSEN F., APPELBAUM F., BARNETT T., SANDERS J., DEEG H., STORB R., DONEY K., BENSINGER W., SHANNONDORCY K., et al.  
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.32, no.4, pp.1103-1109, 1995 (SCI-Expanded)
- CLIV. **FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS**  
BENSINGER W., APPELBAUM F., ROWLEY S., STORB R., SANDERS J., LILLEBY K., GOOLEY T., DEMİRER T., SCHIFFMAN K., WEAVER C., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.10, pp.2547-2555, 1995 (SCI-Expanded)
- CLV. **Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation**  
DEMİRER T., Gooley T., Buckner C., Petersen F., Lilleby K., Rowley S., Sanders J., Storb R., Appelbaum F., Bensinger W.  
Bone Marrow Transplantation, vol.15, no.6, pp.907-913, 1995 (SCI-Expanded)
- CLVI. **FLOW CYTOMETRIC MEASUREMENT OF PROLIFERATION-ASSOCIATED NUCLEAR ANTIGEN P105 AND DNA CONTENT IN IMMUNO-PROLIFERATIVE SMALL-INTESTINAL DISEASE (IPSID)**  
DEMİRER T., UZUNALIMOGLU O., ANDERSON T., KOETHE S., MCFADDEN P., DEMİRER S., UZUNALIMOGLU B., KÜÇÜK N. Ö.  
JOURNAL OF SURGICAL ONCOLOGY, vol.58, no.1, pp.25-30, 1995 (SCI-Expanded)
- CLVII. **HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE FOLLOWED BY ALLOGENEIC**

**BONE-MARROW TRANSPLANTATION IN PATIENTS WITH LYMPHOID MALIGNANCIES WHO HAD RECEIVED PRIOR DOSE-LIMITING RADIATION-THERAPY**

DEMİRER T., WEAVER C., BUCKNER C., PETERSEN F., BENSINGER W., SANDERS J., CLIFT R., LILLEBY K., ANASETTI C., MARTIN P., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.3, pp.596-602, 1995 (SCI-Expanded)

**CLVIII. Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma**

Abouafia D. M., DEMİRER T.

Leukemia and Lymphoma, vol.19, no.1-2, pp.181-184, 1995 (SCI-Expanded)

**CLIX. PERIPHERAL-BLOOD STEM-CELL COLLECTIONS AFTER PACLITAXEL, CYCLOPHOSPHAMIDE, AND RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH BREAST AND OVARIAN-CANCER**

DEMİRER T., ROWLEY S., BUCKNER C., APPELBAUM F., LILLEBY K., STORB R., SCHIFFMAN K., BENSINGER W.

JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.7, pp.1714-1719, 1995 (SCI-Expanded)

**CLX. Myasthenic (Eaton-Lambert) syndrome associated with pulmonary large-cell neuroendocrine carcinoma**

DEMİRER T., Ravits J., Abouafia D.

Southern Medical Journal, vol.87, no.11, pp.1186-1189, 1994 (SCI-Expanded)

**CLXI. INTRATUMOR HETEROGENEITY OF DNA-PLOIDY AND CORRELATIONS WITH CLINICAL STAGE AND HISTOLOGIC GRADE IN PROSTATE-CANCER**

KUCUK O., DEMİRER T., GILMANSACHS A., TAW I., MANGOLD M., SINGH S., WESTERMAN M.

JOURNAL OF SURGICAL ONCOLOGY, vol.54, no.3, pp.171-174, 1993 (SCI-Expanded)

**CLXII. DIET AND STOMACH-CANCER INCIDENCE - A CASE CONTROL STUDY IN TURKEY**

DEMİRER T., ICLİ F., UZUNALIMOĞLU O., KUCUK O.

CANCER, vol.65, no.10, pp.2344-2348, 1990 (SCI-Expanded)

## Articles Published in Other Journals

**I. İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi**

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., ŞENOYMAK M. C., YAVUZ G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.6, no.2, pp.50-55, 2022 (Peer-Reviewed Journal)

**II. Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients**

Kırcalı E., Seval G. C., Bozdağ S. C., Yüksel M. K., Topcuoglu P., Arslan O., Özcan M., Demirer T., İlhan O., Gurman G., et al.

Transplantation and Cellular Therapy, vol.27, no.3, pp.271, 2021 (Scopus)

**III. Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University**

Seval G. C., Bozdağ S. C., Toprak S. K., Yüksel M. K., Topcuoglu P., Arslan O., Özcan M., Demirer T., İlhan O., Tuncali T., et al.

Transplantation and Cellular Therapy, vol.27, no.3, pp.401, 2021 (Scopus)

**IV. The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis**

NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., DEMİRER T., BEKSAÇ M., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.74, 2021 (Peer-Reviewed Journal)

**V. Bir Nakil Merkezinin 11 Yıllık Allojeneik Kök Hücre Nakli Deneyimi**

Kırcalı E., SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., GÜRMAN G., BEKSAÇ M., İLHAN O., et al.

LLM Dergi, vol.4, no.3, pp.50-54, 2020 (Peer-Reviewed Journal)

- VI. **Our Approach in Allogeneic Stem Cell Transplantation: 11 Years of Experience**  
Kırcalı E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., GÜRMAN G., BEKSAÇ M., İLHAN O., et al.  
LLM Dergi, vol.4, no.3, pp.50-54, 2020 (Peer-Reviewed Journal)
- VII. **Our Treatment Approach to Hairy Cell Leukemia**  
ATACA ATILLA P., ATILLA E., KIRCALI E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., BEKSAÇ M., et al.  
Journal of Ankara University Faculty of Medicine, vol.73, no.1, pp.5-8, 2020 (Peer-Reviewed Journal)
- VIII. **Tüylü Hücreli Lösemide Tedavi Yaklaşımımız**  
ATACA ATILLA P., ATILLA E., Kırcalı E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., İLHAN O., AKAN H., BEKSAÇ M., et al.  
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.73, no.1, pp.5-8, 2020 (Peer-Reviewed Journal)
- IX. **Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma**  
Cengiz Seval G., Karaman Z., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T., Gürman G., İlhan O., et al.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.3, no.3, pp.55-59, 2019 (Peer-Reviewed Journal)
- X. **The Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Transplantation for Acute Leukemia**  
ŞAHİN U., ERDAL H., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.  
LLM Dergi, vol.3, no.1, pp.9-13, 2019 (Peer-Reviewed Journal)
- XI. **Akut Lösemide Allojeneik Nakil Öncesi Serum Ferritin Düzeyinin Nakil Sonuçlarına Etkisi**  
ŞAHİN U., HASAN E., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.  
Lösemi Lenfoma Miyelom Hastaları ve Araştırma Eğitimi Birliği Dergisi, vol.3, no.1, pp.1-3, 2019 (Peer-Reviewed Journal)
- XII. **Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center**  
ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.2, no.4, pp.93-97, 2018 (Peer-Reviewed Journal)
- XIII. **Primer Mediastinal Büyük BHücreli Lenfoma Hastalarımızın Tedavi Sonuçlarının Geriye Dönük Değerlendirilmesi**  
ATILLA E., ATACA ATILLA P., Cengiz Seval G., TOPRAK S. K., İLHAN O., ARSLAN Ö., GÜRMAN G., DEMİRER T., ÖZCAN M.  
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları, vol.2, no.3, pp.60-64, 2018 (Peer-Reviewed Journal)
- XIV. **Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.**  
Atilla P. A., Atilla E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., İLHAN O., ARSLAN Ö., GÜRMAN G., et al.  
Hematology/oncology and stem cell therapy, vol.11, no.1, pp.13-17, 2018 (Scopus)
- XV. **Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience**  
ATACA ATILLA P., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., İLHAN O., ARSLAN Ö., GÜRMAN G., et al.  
Hematology Oncology and Stem Cell Therapy, vol.11, no.1, pp.13-17, 2018 (Scopus)
- XVI. **A review of allogeneic hematopoietic stem cell transplantation in metastatic breast cancer**  
Karadurmus N., Sahin U., Basgoz B. B., Arpacı F., DEMİRER T.  
International Journal of Hematology-Oncology and Stem Cell Research, vol.12, no.2, pp.111-116, 2018 (Scopus)
- XVII. **Hairy Cell Leukemia Presenting with Isolated Bone Lesions**



- GÜNDÜZ M., ÖZEN M., YÜKSEL S., KUZU I., DEMİRER T.  
LLM Dergi, vol.1, no.1, pp.14-17, 2017 (Peer-Reviewed Journal)
- XVIII. **Intense Ga-68 Dotatate Uptake in Recurrent MTC Patient**  
SOYDAL Ç., ÖZKAN E., ARAZ M., KÜÇÜK N. Ö., DEMİRER T.  
World Journal of Endocrine Surgery, vol.4, no.3, pp.118-119, 2012 (Scopus)
- XIX. **Intense ga-68 dotatate uptake in recurrent mtc patients**  
SOYDAL Ç., ÖZKAN E., ARAZ M., KÜÇÜK N. Ö., DEMİRER T.  
WORLD JOURNAL OF ENDOCRINE SURGERY, vol.4, no.3, pp.118-119, 2012 (Scopus)
- XX. **CD34+ cells in hematopoietic stem cell transplantation**  
DEMİRER T.  
Advances in Experimental Medicine and Biology, vol.534, pp.107-118, 2003 (Scopus)
- XXI. **The Role of ABO Incompatibility in Allogeneic Peripheral Blood Stem Cell Transplant.**  
Arslan Ö., Coşkun H. Ş., Arat M., Soydan E., Özcan M., Gürman G., Çelebi H., Demirer T., Akan H., İlhan O., et al.  
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.19, no.3, pp.401-9, 2002 (Scopus)
- XXII. **Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy**  
Bensinger W., Buckner C., Shannon-Dorcy K., Rowley S., Appelbaum F., Benyunes M., Clift R., Martin P., DEMİRER T., Storb R., et al.  
Blood, vol.88, no.11, pp.4132-4138, 1996 (Scopus)
- XXIII. **Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy**  
Bensinger W., Buckner C., Rowley S., DEMİRER T., Storb R., Appelbaum F., Hutchinson F.  
Bone Marrow Transplantation, vol.17, no.SUPPL. 2, 1996 (Scopus)
- XXIV. **Transplantation of allogeneic peripheral blood stem cells.**  
Bensinger W., Buckner C., DEMİRER T., Storb R., Appelbaum F.  
Bone marrow transplantation, vol.17 Suppl 2, 1996 (Scopus)
- XXV. **Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia**  
DEMİRER T., Buckner C., Appelbaum F., Petersen F., Rowley S., Weaver C., Lilleby K., Sanders J., Chauncey T., Storb R., et al.  
Bone Marrow Transplantation, vol.15, no.6, pp.915-922, 1995 (Scopus)
- XXVI. **Optimization of peripheral blood stem cell collection.**  
DEMİRER T., Bensinger W.  
Current opinion in hematology, vol.2, no.3, pp.219-226, 1995 (Scopus)
- XXVII. **Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease**  
DEMİRER T., Buckner C. D., Lilleby K., Weaver C., Longin K., Appelbaum F. R., Bensinger W. I.  
Cancer, vol.74, no.2, pp.715-721, 1994 (Scopus)
- XXVIII. **Four varied cases of intravascular lymphomatosis and a literature review**  
DEMİRER T., Dail D. H., Aboulafia D. M.  
Cancer, vol.73, no.6, pp.1738-1745, 1994 (Scopus)

## Books & Book Chapters

### I. **Future Perspectives for Haploidentical Stem Cell Transplantation**

ŞAHİN U., DEMİRER T.

in: Haploidentical Stem Cell Transplantation: An Emerging Treatment Modality, TANER DEMİRER, Editor, Humana Press, CHAM, pp.189-198, 2017

## Refereed Congress / Symposium Publications in Proceedings

- I. **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE**  
Karakaya B., Yilmaz H., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., Yuksel M. K., Arslan Ö., Özcan M., Demirer T., et al.  
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.457-458
- II. **ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE**  
Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., Arslan Ö., Demirer T., Gurman G., Beksac M., et al.  
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.301-302
- III. **EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES**  
Beksac M., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T., İlhan O., et al.  
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, France, 23 April 2023, vol.58, pp.107
- IV. **The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes**  
Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., Arslan Ö., Demirer T., İlhan O., Gurman G., et al.  
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.12673-12674
- V. **The efficacy and safety of second allogeneic hematopoietic stem cell transplantation**  
TOPRAK S. K., KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
2022 ASCO Annual Meeting, United States Of America, 01 June 2022
- VI. **Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome**  
KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., BEKSAÇ M., et al.  
48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), United States Of America, 19 - 22 March 2022
- VII. **Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience**  
İLHAN O., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), United States Of America, 19 - 22 March 2022
- VIII. **İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ**  
KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.  
14. Ulusal kemik iliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022
- IX. **GRAFT VERSUS HOST HASTALIĞI PROFİLAKSİSİNDE ATG VE POST CY KULLANIMININ NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ**  
Karakaya B., ŞAHİN Y. İ., MAMMADLI H., Yavuz G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
14. Ulusal kemik iliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022
- X. **THE OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN LYPHOMA**

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.

63TH ASH CONGRESS, ATLANTA, United States Of America, 8 - 11 December 2021

- XI. **The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma**  
İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
63rd ASH Annual Meeting and Exposition, 11 December 2021
- XII. **PROFLAKTİK DEFİBROTİD SOS DIŞINDA AKUT GRAFT VS HOST HASTALIĞINDA DA ETKİN**  
KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., YAVUZ G., KARAKAYA B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.  
47. Ulusal Hematoloji Kongresi, 04 November 2021
- XIII. **Allojenik Kök Hücre Nakli Hastalarında Peritransplant Metronidazol Kullanımıyla Akut GVHD Riskinin İlişkisi**  
KIRCALI E., SEVAL G. C., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
13. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 2 - 03 April 2021
- XIV. **MULTİPL MİYELOMDA OTOLOG PRİFERİK KÖK HÜCRE NAKLİ SONRASI ERKEN NÜKSÜ BELİRLEMEDE CIBMTR, ISS VE R-ISS SKORLAMA SİSTEMLERİNİN KARŞILAŞTIRILMASI**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., TUNCALI T., et al.  
13. Ulusal kemik iliği Transplantasyonu ve Hücre Tedaviler Kongresi, 02 April 2021
- XV. **ALLOJENİK KÖK HÜCRE NAKLİ HASTALARINDA PERİTRANSPLANT METRONİDAZOL KULLANIMIYLA AKUT GVHD RİSKİNİN İLİŞKİ**  
KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
13. Ulusal kemik iliği Transplantasyonu ve Hücre Tedaviler Kongresi, 02 April 2021
- XVI. **Relaps/Refrakter Hodgkin Lenfoma Hastalarında Allojenik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi**  
KOYUN D., ŞAHİN U., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., BEKSAÇ M., et al.  
13. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 2 - 03 April 2021
- XVII. **Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi**  
Öztürk C., KIRCALI E., KOYUN D., YILMAZ H., YAVUZ G., KARAKAYA B., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.  
13. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 2 - 03 April 2021
- XVIII. **THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION**  
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., KARAKAYA B., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., et al.  
8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.38, no.71, pp.1-81
- XIX. **The impact of pretransplant immunomodulatory drugs on cmv reactivation**  
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., KARAKAYA B., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., et al.  
8th International congress on leukemia lymphoma myeloma, 2021, 21 May 2021
- XX. **Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients**  
KIRCALI E., SEVAL G. C., ÖZTÜRK C., BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 8 - 12 February 2021

- XXI. **Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University**  
SEVAL G. C., BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., TUNCALI T., et al.  
Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 08 February 2021
- XXII. **AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR**  
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., DALVA K., GÜRMAN G., et al.  
42.Ulusal Hematoloji Kongresi, Turkey, 28 - 30 October 2020
- XXIII. **Foliküler lenfomada bazal PET'te toplam metabolik tümör hacmi ve toplan lezyon glikolizinin prognostik önemi.**  
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., ÖZKAN E., ARAZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., USLU A., et al.  
46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020
- XXIV. **Flamsa-Based High-Dose Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Stem Cell Transplantation (Allo-Hsct): Is It Effective in Patients With Primary Refractory Or Relapsed Acute Leukemia?**  
CENGİZ SEVAL G., EKİN K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.  
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020
- XXV. **The Influence Of Anti-Thymocyte Globulin (Atg) On The Outcomes Of Patients With Aml W/Wo Measurable Residual Disease (Mrd) At The Time Of Unrelated Donor Transplantation**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALI E., BALTACI M. A., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020
- XXVI. **Role Of Chimerism And Flow-Cytometric Monitoring Of Measurable Residual disease (Mrd) After Allogeneic Hematopoietic Stem Cell Transplantation (Allohsct) In Predicting Relapse In Acute Myeloid Leukemia (AML)**  
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020
- XXVII. **Treatment Of Thrombocytopenia After Allogeneic Stem Cell Transplantation with Eltrombopag**  
KIRCALI E., CENGİZ SEVAL G., KOYUN D., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020
- XXVIII. **Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.**  
Demirer T., Seval G. C., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Gurman G., Ilhan O., Beksac M., Ozcan M.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38
- XXIX. **CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ**  
CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., USLU A., DALVA K., et al.  
12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, Turkey, 5 - 07 March 2020
- XXX. **AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ**

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., GÜRMAN G., YÜKSEL M.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 5 - 07 March 2020

**XXXI. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM**

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., GÜRMAN G., İLHAN O., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedavileri Kongresi, Turkey, 5 - 07 March 2020

**XXXII. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**

CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2020, 19 - 23 February 2020

**XXXIII. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow**

CENGİZ SEVAL G., USLU A., KIRCALI E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., DALVA K., ARSLAN Ö., ÖZCAN M., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 February 2020

**XXXIV. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**

SEVAL G. C., Öztürk n., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

61st ASH Annual Meeting, 7 - 10 December 2019

**XXXV. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia? KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.**

61st ASH Annual Meeting and Exposition, 7 - 10 December 2019

**XXXVI. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia? Kircali E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.**

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**XXXVII. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis**

CENGİZ SEVAL G., Ozturk N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**XXXVIII. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data**

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., Yuksel M. K., TOPÇUOĞLU P., KUZU I., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134

**XXXIX. KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL'DEN BAĞIMSIZ PROGNOZİK BİR FAKTOR OLABİLİR Mİ?**

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., Aral D., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019

- XL. **HANGİSİ, ORJİNAL İMATİNİB Mİ JENERİK Mİ KRONİK MYELOİD LÖSEMİDE DAHA ETKİN?**  
KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.  
45. Ulusal Hematoloji Kongresi, 31 October 2019
- XLI. **YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ**  
TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., Aral D., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.  
45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019
- XLII. **Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation**  
CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.  
17th International Myeloma Workshop, 12 - 15 September 2019
- XLIII. **Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions**  
İLHAN O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.382
- XLIV. **Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased OS in myeloma patients after ASCT?**  
YÜKSEL M., CENGİZ SEVAL G., Uslu A., Kircili E., KOYUN D., Ozturk C., Ozdemir Z. N., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.505-506
- XLV. **Is mobilization with chemotherapy effect response in the multiple myeloma?**  
CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., Akan H., et al.  
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.500
- XLVI. **Can Nelarabine Rescue The Graft After Allogeneic Hematopoietic Stem Cell Transplantation In T-All ?**  
YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., BEKSAÇ M., et al.  
24 Congress of the European Hematology Association, 13 - 16 June 2019
- XLVII. **Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?**  
İlhan O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., Akan H., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XLVIII. **Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.**  
DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., Akan H., İLHAN O., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XLIX. **CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**  
SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN

O., AKAN H., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019

- L. **retrospective analysis of 149 unselected patients with mantle cell lymphoma confirms prognostic relevance of mmp1: single center experience**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.  
ICLLM 2019, 02 May 2019
- LI. **CAN ELTROMBOPAG TREAT THE THROMBOCYTOPENIA AFTER STEM CELL TRANSPLANTATION**  
Yüksel M., Kırçalı E., Cengiz Seval G., Koyun D., Uslu A., Öztürk C., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Beksaç M., et al.  
7th International Congress on Leukemia Lymphoma, İstanbul, Turkey, 2 - 04 May 2019
- LII. **İyi Riskli Aml'de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi**  
PEKCAN G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LIII. **Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmeye Kimerizm İle Mrd Karşılaştırılması**  
CENGİZ SEVAL G., ULAŞ B. B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LIV. **Miyelom Hastalarında Önce Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi?**  
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LV. **Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimiz**  
Kırçalı E., Cengiz Seval G., Koyun D., Civriz Bozdağ S., Topçuoğlu P., Özcan M., Beksaç M., İlhan O., Arslan Ö., Gürman G., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2019
- LVI. **T-All Hastalarında Allojeneik Hematopoietik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?**  
CENGİZ SEVAL G., USLU A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LVII. **Posttransplant Lenfositöz Önemli Bir Parametre midir?**  
CENGİZ SEVAL G., USLU A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., AKAN H., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LVIII. **Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi?**  
CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., AKAN H., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücreyel Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LIX. **Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)**  
CENGİZ SEVAL G., Atilla E., Ulas B., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, United States Of America, 13 - 24 February 2019, vol.25

- LX. MİYELOM HASTALARINDA OHKHN ÖNCESİ KULLANILAN İLAÇLARIN CMV REAKTİVASYONU ÜZERİNE SAĞKALIMIAZALTICI ETKİSİ OLABİLİR Mİ?**  
YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., NARLI ÖZDEMİR Z., ÇINAR G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.  
11. Ulusal Kemik İliği Transplantasyonu ve Hücresele Tedaviler Kongresi, Turkey, 1 - 03 March 2019
- LXI. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., İLHAN O., AKAN H., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019
- LXII. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER**  
CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DEMİRER T., et al.  
7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019
- LXIII. İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi**  
AKKUŞ E., FİDAN Ç., KUŞTAŞ A. A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Turkey, 5 - 07 April 2018, vol.16, pp.44
- LXIV. Comparison of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience**  
TOPÇUOĞLU P., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
60th ASH Annual Meeting and Exposition, 01 December 2018
- LXV. Comparison of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience**  
TOPÇUOĞLU P., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
60th ASH Annual Meeting, san diego, United States Of America, 29 November - 05 December 2018, vol.132, pp.4673
- LXVI. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience**  
GÜRMAN G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132
- LXVII. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients**  
Atilla E., TOPÇUOĞLU P., AKKUŞ E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T., ÖZCAN M., BEKSAÇ M., İLHAN O., et al.  
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132
- LXVIII. Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi**  
DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.  
44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2018, pp.245-246
- LXIX. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ**



KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., TOPÇUOĞLU P., GÜRMAN G., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018

**LXX. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILANALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİLSONUÇLARINA ETKİLERİ**

KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., TOPÇUOĞLU P., GÜRMAN G., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018

**LXXI. AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNNAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ**

CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., ARSLAN Ö., ÖZCAN M., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018

**LXXII. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma**

CENGİZ SEVAL G., Serteselen E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., Arslan O., ÖZCAN M., DEMİRER T., GÜRMAN G., İLHAN O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.338

**LXXIII. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation**

Uslu A., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., GÜRMAN G., Demirer T., Arslan O., Ozcan M., TOPRAK S. K., Topcuoglu P., İlhan O.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.161-162

**LXXIV. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen**

İlhan O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.272-273

**LXXV. Is post-transplant albumin a predictor of early transplant complications?**

TOPÇUOĞLU P., CENGİZ SEVAL G., AKKUŞ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., Akan H., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.344-345

**LXXVI. The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4 (+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect**

YÜKSEL M., Ozdemir Z. N., Sahin U., ÇAĞDAŞ AYVAZ D. N., Atikcan D. T., Serteselen E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., Arslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.533-534

**LXXVII. Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience**

Cengiz Seval G., BULAT B., Ozel F., Tasci O., Kuzu I., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.

ASCO Annual Meeting 2018, 1 - 05 June 2018, vol.36, pp.19525

**LXXVIII. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR**

GÜNDÜZ M., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., AKAN H., et al.

10. ULUSAL KEMİK İLİĞİTRANSPLANTASYONU VEHÜCRESEL TEDAVİLER KONGRESİ, Antalya, Turkey, 1 - 03

March 2018

- LXXXIX. **Allojeneik Hematopoetik Kk Hcre Nakli Sonrası Akut Myeloid Lsemi Nksnn Ynetimi ve Prognozu**  
AHİN U., GNDZ M., MERTER M., NARLI ZDEMİR Z., ZEN M., CİVRİZ BOZDAĞ S., YKSEL M., TOPRAK S. K., ARSLAN ., ZCAN M., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018
- LXXX. **ALLOJENEİK HEMATOPOETİK KK HCRE NAKLİ SONRASI AKUT MYELOİD LSEMİ NKSNN YNETİMİ VE PROGNOZU**  
AHİN U., GNDZ M., MERTER M., NARLI ZDEMİR Z., ZEN M., CİVRİZ BOZDAĞ S., YKSEL M., TOPRAK S. K., ARSLAN ., ZCAN M., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018, pp.126-127
- LXXXI. **MYELOFİBROZİSTE ALLOJENEİK HEMATOPOETİK KK HCRE NAKLİ SONUÇLARI: TEK MERKEZ DENEYİMİ**  
CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YKSEL M., TOPÇUOęLU P., ARSLAN ., DEMİRER T., GRMAN G., İLHAN O., AKAN H., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, 01 March 2018
- LXXXII. **KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?**  
CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., YKSEL M., ARSLAN ., ZCAN M., DEMİRER T., GRMAN G., İLHAN O., AKAN H., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, 01 March 2018
- LXXXIII. **Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma**  
İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YKSEL M., TOPÇUOęLU P., ARSLAN ., ZCAN M., DEMİRER T., Akan H., et al.  
Blood and Marrow Transplantation Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, United States Of America, 21 - 25 February 2018, vol.24
- LXXXIV. **Ph Negatif ALL'de 1. Tam Remisyonda Yapılan Pekiştirme Tedavileri Nakil Sonrası Başarıyı Arttırır**  
NARLI ZDEMİR Z., AHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YKSEL M., TOPÇUOęLU P., ARSLAN ., DEMİRER T., AKAN H., İLHAN O., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018
- LXXXV. **AKUT GRAFT VERSUS HOST HASTALIęI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ**  
NARLI ZDEMİR Z., CENGİZ SEVAL G., USLU A., ZTRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOęLU P., ARSLAN ., ZCAN M., DEMİRER T., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2018
- LXXXVI. **ITK Gen Defektine Baęlı CD4+ T Hcre Yetmezlięi Olan Eriřkinde Allojeneik Hematopoietik Kk Hcre Naklinin Sonuları**  
YKSEL M., NARLI ZDEMİR Z., AHİN U., CENGİZ SEVAL G., AęDAř AYVAZ D., ATİKCAN D. T., SERTESEN E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOęLU P., et al.  
10. Ulusal Kemik İlięi Transplantasyonu ve Hresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2018, pp.138
- LXXXVII. **Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma**  
Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., Topcuoglu P., Ozel F., CİVRİZ BOZDAĞ S., YKSEL M., Arslan O., Ozcan M., Demirer T., et al.  
59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130
- LXXXVIII. **Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma**  
Atilla E., TOPRAK S. K., CİVRİZ BOZDAĞ S., YKSEL M., Topcuoglu P., Akan H., Arslan O., Demirer T., Beksac M., Ilhan O., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130

- LXXXIX. **Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler**  
Aydın T., MERTER M., ŞAHİN U., Pekcan G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.53
- XC. **OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?**  
MERTER M., Güleç B., Özcan G., Zehra Özdemir Z., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., ÖZCAN M., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.220
- XCII. **İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi**  
AKKUŞ E., KUŞTAŞ A. A., Pekcan G., MERTER M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.98-99
- XCIII. **Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation**  
MERTER M., Köken K., YÜKSEL M., Demir E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France, 26 - 29 March 2017, vol.52, pp.141-142
- XCIV. **peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience**  
seval G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., et al.  
ebmt 2017, 26 - 29 March 2017
- XCV. **Autologous Stem Cell Trnasplantation for Mantle Cell Lymphoma: A Single Center Exprience**  
TOPRAK S. K., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., ARAT M., et al.  
Exprience22nd Congress of the European Hematology Association, 22 June - 25 May 2017
- XCVI. **Allojeneik stem cell transplantation results in our myelodysplastic syndrome (MDS) patientes**  
GÜRMAN G., ATACA ATİLLA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T., et al.  
patientes53rd Annual Meeting Jun 2-6, 2017, 2 - 06 June 2017
- XCVII. **Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantationd for acute myeloid leukemia**  
GÜRMAN G., AYDEMİR GÜLOKSUZ G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., ARSLAN Ö., et al.  
leukemia53rd Annual Meeting, 2 - 06 June 2017
- XCVIII. **A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be**  
PEKCAN G., YÜKSEL M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
6th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 11 - 13 May 2017, pp.112
- XCVIII. **Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization**  
MERTER M., KÖKEN K., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 May 2017
- XCIX. **Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.**

GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Topcuoglu P., Ozcan M., Arslan O., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35

C. **A single center experience with two decades of follow-up on patients with hairy cell leukemia.**

İLHAN O., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., ÖZCAN M., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35

CI. **Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease**

MERTER M., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017

CII. **Herpes SimplexVirus infection in patients after allogeneic hematopoetic stem cell transplantation**

ATILLA E., ÖZEL F., YILMAZ V., ATACA ATILLA P., ATEŞAĞAOĞLU B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., et al.

43rd Annual Meeting Of EBMT, 26 - 29 March 2017

CIII. **Peripheral blood stem cell mobilization and collection from elderly patients (265 years) with multiple myeloma: A single center experience**

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 March 2017

CIV. **Large Unsaturated Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation**

MERTER M., KÖKEN K., YÜKSEL M., DEMİR N., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017

CV. **Acute GVHD and untreated/haploidentical Trnasplants increses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients**

TOPÇUOĞLU P., ATILLA E., ATACA ATILLA P., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., DEMİRER T., ARSLAN Ö., ÖZCAN M., et al.

43rd Annual Meeting Of EBMT, 26 - 29 March 2017

CVI. **Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients**

GÜRMAN G., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

BMT Tandem Meetings, 22 - 26 February 2017

CVII. **Comparison of Reduced Intensity Conditioning (RIC) Regimen and Myeloablative Conditioning (MAC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Adult Patients with Acute Leukemia**

GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 3 - 06 December 2016, vol.128

CVIII. **TROMBOTİK MİKROANJİOPATİDE TERAPÖTİKPLAZMA DEĞİŞİMİ**

ATILLA E., ATACA ATILLA P., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., ARSLAN Ö., DEMİRER T., AKAN H., BEKSAÇ M., et al.

42. Ulusal Hematoloji, Turkey, 19 - 22 October 2016

CIX. **AllojeneikKökHücreNakliHastalarımızdaGelişenKataterTrombozları**

ATILLA E., YALÇINER M., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016

- CX. ALLOJENEİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA PERİTRANSPLANT ALBUMİN DÜŞÜŞÜ İLE GVHD İLİŞKİSİ**  
MERTER M., ŞAH F. T., ŞAHİN U., YALÇINER M., KOCABAY H. E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., ARSLAN Ö., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXI. PERİFERİK T HÜCRELİ LENFOMALARDA OTOLOGHEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU TEK MERKEZ DENEYİMİ**  
ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXII. ANTI HLA ANTİKOR VARLIĞININ ALLOJENEİK KÖKHÜCRE NAKLİ YAPILAN HASTALARDA ENGRAFMANÜZERİNE ETKİSİ TEK MERKEZ DENEYİMİ**  
MERTER M., AYDOĞAN M., TEKEŞ M. A., ŞAHİN U., AYYILDIZ Ö. M., KOCABAY H. E., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXIII. Allojeneik Kök Hücre Nakli Olan Akut Lösemilerde Hazırlık Rejimlerinin Karşılaştırılması**  
ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016
- CXIV. ALLOJENEİK KÖK HÜCRE NAKLİ OLAN AKUT LÖSEMİLERDE HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASI**  
GÜLÖKSÜZ G. A., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016
- CXV. Approach to Hairy Cell Leukemia HCL 31 years of Experience**  
KIRCALI E., ATACA ATILLA P., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., DEMİRER T., et al.  
EHA 2016, 9 - 12 June 2016
- CXVI. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma ASCO Annual Meeting J Clin Oncol 34 2016 suppl abstr e 19001**  
İLHAN O., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
ASCO, 3 - 07 June 2016
- CXVII. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma Subcategory**  
İLHAN O., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
ASCO 2016, ABD, 3 - 07 June 2016
- CXVIII. Are Age and JAK2V617F Mutation Related to Thrombosis in Chronic Myeloproliferative Diseases**  
ATILLA E., ATACA ATILLA P., TOPRAK S. K., KAYGUSUZ G., KUZU I., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., DEMİRER T., et al.  
24th Biennial International Congress on Thrombosis, 4 - 07 May 2016
- CXIX. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.**  
İlhan O., Atilla E., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Arslan O., Ozcan M., Demirer T., et al.  
Annual Meeting of the American Society of Clinical Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- CXX. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma**  
İLHAN O., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., ARSLAN Ö.,

ÖZCAN M., DEMİRER T., et al.

ASCO, 3 - 07 June 2016

- CXXI. **AKTİF HASTALIKLI AKUT LÖSEMİDE ATG VEHAZIRLIK REJİMİ İLE ALLOJENİK NAKİL SONRASICMV REAKTİVASYONUNUN PROGNOZA ETKİSİ**  
GÜNDÜZ M., ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., et al.  
9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016
- CXXII. **PAROKSİSMAL NOKTÜRNAL HEMOGLOBİNÜRİHASTALARINDA ALLOJENEİK HEMATOPOETİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ**  
NARLI ÖZDEMİR Z., TOPRAK S. K., TOPÇUOĞLU P., ŞAHİN U., GÜNDÜZ M., ATILLA E., ATACA ATILLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., et al.  
9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016
- CXXIII. **HAİRY CELL LÖSEMİ HCL VAKALARIMIZ TEKMERKEZ DENEYİMİ**  
Kırcalı E., ATACA P., ATILLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., İLHAN O., DEMİRER T., et al.  
41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CXXIV. **Clinical Allogeneic Transplantation Acute and Chronic GVHD Immune Reconstitution**  
GÜRMAN G., ATACA P., ATILLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., AKAN H., ARSLAN Ö., TOPÇUOĞLU P., et al.  
57th ASH Annual Meeting & Exposition, 5 - 08 December 2015
- CXXV. **Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?**  
Atilla E., Ataca P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., BEKSAÇ M., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CXXVI. **Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients**  
GÜRMAN G., Ataca P., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., Akan H., ARSLAN Ö., TOPÇUOĞLU P., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CXXVII. **Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation**  
Mertter M., Atilla E., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., et al.  
57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126
- CXXVIII. **Allojeneik Hematopoietik Kök Hücre Nakli AHKHN Hastalarında Gelişen Üst ve Alt Solunum Yolları Viral Enfeksiyonları**  
ATILLA E., ATACA P., ŞAHİN D., DOLAPÇI G. İ., TEKELİ F. A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
Febril Nötropeni Simpozyumu, Turkey, 28 - 30 November 2015
- CXXIX. **Ph Negatif ALL Hastalarında Allojenik Kök Hücre Nakli Öncesi Tedavilerin Klinik Seyir ile İlişkisi**  
NARLI ÖZDEMİR Z., EKİN K., ATACA P., ATILLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., BEKSAÇ M., İLHAN O., et al.  
41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015
- CXXX. **PH NEGATİF ALL HASTALARINDA ALLOJENİK KÖKHÜCRE NAKLİ ÖNCESİ TEDAVİLERİN KLİNİK SEYİRİLE İLİŞKİSİ**  
Özdemir Z. N., Kırcalı E., ATACA P., ATILLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., BEKSAÇ M., İLHAN O., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

CXXXI. **ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA ANTİ HLA ANTİKORLARI İLE ENGRAFMAN YETMEZLİĞİ İLİŞKİSİ TEK MERKEZ DENEYİMİ**  
MERTER M., ŞAHİN U., ateşagaoglu b., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 23 October 2015

CXXXII. **HODGKİN HL VE HODGKİNDİŞİ LENFOMALI HDL HASTALARDA TEDAVİ SONRASI GEÇ DÖNEMDEYÜKSEK HEMATOKRİT DEĞERLERİ HL İLEERİTROSİTOZ ARASINDA İLİŞKİ Mİ VAR**  
Ateşagaoglu B., ATACA P., Tuncay G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., DEMİRER T., İLHAN O., BEKSAÇ M., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

CXXXIII. **ALLOJENEİK KÖK HÜCRE TRANSPLANTASYONHASTASINDA KRONİK GRAFT VERSUS HOSTHASTALIĞININ GENEL SAĞKALIM ÜZERİNE ETKİSİ**  
ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., AKAN H., ARSLAN Ö., TOPÇUOĞLU P., BEKSAÇ M., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

CXXXIV. **ALLOJENEİK HEMATOPOİETİK KÖK HÜCRENAKLİNDE İKİ FARKLI ANTİTİMOSİTGLÖBULİN PREMEDİKASYON PROTOKOLÜNÜN KARŞILAŞTIRILMASI**  
MERTER M., ŞAHİN U., Ateşagaoglu B., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

CXXXV. **Allagenic stemcell transplantation results in our myelodysplastic syndrome MDS patient**  
GÜRMAN G., ATACA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., KURT YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T.

ASCO -2015, 29 - 02 May 2015

CXXXVI. **Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT A Single Center Experience 41st Annual Meeting of the European Society for Blood and Marrow**  
MERTER M., uğur ş., gündüz m., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

(Allo-HSCT): A Single Center Experience. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, İstanbul, 22-25 Mayıs 2015., 22 - 25 May 2015

CXXXVII. **Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma**  
ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., BEKSAÇ M., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21-23 May 2015. Turkish Society of Hematology, Proceedings & Abstract Book, abstract # 0109, poster # PS-101 pp 175., 21 - 23 May 2015

CXXXVIII. **AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS 60 YEARS WITH MYELOMA OR LYMPHOMA**

ATİLLA E., GÜNDÜZ M., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., MELTEM K. Y., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 May 2015

CXXXIX. **Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.**  
GÜRMAN G., Ataca P., Aydın T., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Topcuoglu P., Ozcan M., Demirer T., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

CXL. **Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or Lymphoma**  
ATİLLA E., MEHMET G., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.

Best of ASBMT Tandem Meetings, Poster Presentation, Turkey, 27 - 28 March 2015

- CXLI. DIFFERENT DOSES OF ATG IN THE CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**  
PEKCAN G., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ATEŞ O., ÖZCAN M., DEMİRER T.  
41.EBMT MEETING, 24 - 26 March 2015
- CXLII. THE RELAPSE IN ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION NO APPROACHES HAVE BEEN SUPERIOR YET**  
TOPÇUOĞLU P., GÜNDÜZ M., ÖZEN M., ATILLA E., ATACA P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
41.EBMT MEETING, 24 - 26 March 2015
- CXLIII. impact pf pretransplant serum ferritinon outcomes of allogeneic hematopoeitic stem cell transplantationfor acute leukemia**  
ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O.  
41.ebmt meeting, 22 - 25 March 2015
- CXLIV. Autologus stem cell transplantation in elderly patients with myeloma and lymphoma single center experience**  
GÜNDÜZ M., ATILLA E., ATACA P., PEKCAN G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
41.EBMT KONGRESİ, 24 - 26 March 2015
- CXLV. Different Doses of Anti Thymocyte Globulin ATG in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S228**  
GÜLTEKİN P., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015
- CXLVI. s it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation HSCT using Plasma Exchange PE A Single Center s Experience**  
YÜKSEL M., Gultekin G., Edipoglu E., Bay M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., BEKSAÇ M., et al.  
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 22 - 25 March 2015
- CXLVII. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S483**  
UĞUR Ş., MERTER M., ATAŞAĞAOĞLU B., ERDAL H., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., et al.  
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015
- CXLVIII. Upper and Lower Respiratory Tract Infections by Respiratory Viruses by Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Single Center Experience**  
ŞAHİN D., ATILLA E., CİVRİZ BOZDAĞ S., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., et al.  
41th EBMT Meeting, 22 - 25 March 2015
- CXLIX. Generic Bioequivalent Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S440**  
TOPÇUOĞLU P., GÜLTAY D., ÖZTÜRK N., KILIÇ Ö., OKAY M., ERASLAN KARADAĞ Y., ÇINAR H., ATACA P., ATILLA E., CİVRİZ BOZDAĞ S., et al.  
41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015
- CL. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic**



### **Stem Cell Transplantation (Allo-HSCT)**

Sahin U, Merter M, Atesagaoglu B, Erdai H, CİVRİZ BOZDAĞ S, TOPRAK S. K., YÜKSEL M., Topcuoglu P., Arslan O, Ozcan M., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Turkey, 22 - 25 March 2015

- CLI. **Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation**  
Pekcan G., Atesagaoglu B., Merter M., Topcuoglu P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., Ates O., Ozcan M., Demirer T., et al.  
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Turkey, 22 - 25 March 2015
- CLII. **Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center**  
Sahin U, Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CLIII. **Do FMS-like Tyrosine Kinase 3 and Nucleophosmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?**  
Gunduz M., Ataca P., Ozen M., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., DEMİRER T., BEKSAÇ M., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CLIV. **Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients**  
TOPÇUOĞLU P., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., Konuk N., Akan H., İLHAN O., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CLV. **Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience**  
Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., Pekcan G., Merter M., Gunduz M., Ozen M., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CLVI. **Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation**  
TOPÇUOĞLU P., Gunduz M., Ozen M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., DEMİRER T., İLHAN O., Akan H., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CLVII. **Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?**  
İLHAN O., Ataca P., Atilla E., TOPRAK S. K., KAYGUSUZ G., KUZU I., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.  
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- CLVIII. **STEM CELL MOBILIZATION IN ELDERLY MULTIPLE MYELOMA PATIENTS: SINGLE CENTER EXPERIENCE**  
TOPRAK S. K., CENGİZ SEVAL G., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., DEMİRER T., GÜRMAN G., AKAN H., BEKSAÇ M., et al.  
19th Congress of the European Hematology Association, 12 June 2014
- CLIX. **AKRABA DIŐI ALLOJENEİK HEMATOPOETİK HÜCRE NAKLİNDE HLA UYUŐUMUNUN ETKİŐİ-TEK MERKEZ DENEYİMİ**  
CENGİZ SEVAL G., TOPÇUOĞLU P., ÖZEN M., GÜNDÜZ M., ATILLA E., DALVA K., ARSLAN Ö., ÖZCAN M., DEMİRER T.,

İLHAN O., et al.

8. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 06 March 2014

- CLX. **OTOLOG HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASINDA GELİŞEN BİR CMV RETİNİT VAKASI**  
CENGİZ SEVAL G., TOPÇUOĞLU P., İDEMEN C., DEMİRER T.  
8. Ulusal Kemik İliği Transplantasyonu ve Hücre Tedaviler Kongresi, 06 March 2014
- CLXI. **Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation**  
GÜRMAN G., Atilla E., Ozen M., Kubilay P., Yilmaz G., Gunduz M., ARSLAN Ö., ÖZCAN M., DEMİRER T., Akan H., et al.  
BMT Tandem Meetings, Texas, United States Of America, 26 February - 02 March 2014, vol.20
- CLXII. **Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal Hemoglobinuria**  
Demirer T., Baslar S., Uysal V. A., Beksac M., Ozen M., Konuk N., Ilhan O., Arslan O., Ozcan M., Topcuoglu P., et al.  
55th Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America, 7 - 10 December 2013, vol.122
- CLXIII. **The impact of histopathological subtype of cutaneous chronic GvHD on alloHSCT outcome: lichenoid versus sclerodermoid**  
SOYDAN E., CENGİZ SEVAL G., ŞANLI H., TOPÇUOĞLU P., UĞUR BİLGİN A., BAKANAY ÖZTÜRK Ş. M., ARSLAN Ö., ÖZCAN M., DEMİRER T., AKAN H., et al.  
33rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 25 March 2007
- CLXIV. **Refrakter ve Relaps Akut Myeloblastik Lösemide EMA Kurtarma Rejimi Sonuçlarımız**  
TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., GÜRMAN G., DEMİRER T., AKAN H., KONUK N., UYSAL A., BEKSAÇ M., et al.  
XXXII. Ulusal Hematoloji Kongresi, Turkey, 8 - 10 November 2006
- CLXV. **MULTİPL MİYELOMA VE MALİN LENFOMALI HASTALARDA OTOLOG PERİFERİK KÖK HÜCRE TOPLANMASINDA AFEREZ GÜN SAYISI ÖNGÖRÜLEBİLİR Mİ? - ANKARA HESAPLAMA FORMÜLÜ**  
ARAT M., CENGİZ SEVAL G., SOYDAN E., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., GÜRMAN G., DALVA K., BEKSAÇ M., et al.  
32. Ulusal Hematoloji Kongresi, 08 November 2006
- CLXVI. **European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the French ITAC group and the EBMT solid tumour working party**  
Barkholt L., Bregni M., Remberger M., Blaise D., Peccatori J., Massenkeil G., Pedrazzoli P., Zambelli A., Bay J., Francois S., et al.  
32nd Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, Hawaii, United States Of America, 16 - 20 February 2006, vol.12, pp.21
- CLXVII. **Allogeneic haematopoietic cell transplantation in acute myeloblastic laekemia: Ibni Sina experience (1989-2004)**  
Ilhan O., Topcuoglu P., Arat M., Soydan E., TOPRAK S. K., YÜKSEL M., Ustun C., Celebi H., Dilek I., Arslan O., et al.  
31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005, vol.35
- CLXVIII. **Allogeneic hemapoietic progenitor cell collection using four different cell separators: A retrospective comparative analysis.**  
Arat M., Arslan O., Soydan E., Ayyildiz E., Dalva K., Tol M., Ozcan M., GÜRMAN G., Demirer T., Akan H., et al.  
46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104
- CLXIX. **The comparison of myeloablative versus reduced intensity conditioning regimen in ABO mismatched allogeneic hematopoietic cell transplantation.**  
Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., Gorman G., Demirer T., Akan H., BEKSAÇ M., et al.  
46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104
- CLXX. **Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Turnouts Working Party**

Bregni M, Peccatori J, Barkholt L, Ringden O, Pedrazzoli P, Martino R, Lenhoff S, Corradini P, Demirer T, Niederwieser D.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

**CLXXI. High-dose thiotepa, melphalan and carboplatin followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation**

Demirer T, Soydan E, Fen T, Ilhan O, Ayli M, Arat M, Ozcan M, Gunel N, Arslan O, Genc Y, et al.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33

**CLXXII. Graft-versus-tumor effect following reduced-intensity allogeneic stem cell transplantation in renal cell cancer. On behalf of the EBMT solid tumours working party.**

Bregni M, Barkholt L, Peccatori J, Pedrazzoli P, Remberger M, Carminati O, Ciceri F, Siena S, Martino R, Sierra J, et al.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102

**CLXXIII. Comparison of three conditioning regimens used in high-dose therapy of malign lymphomas: CBV-ICE-CTM**

Soydan E, Arat M, Topcuoglu P, Demirer T, Arslan O, Ozcan M, BEKSAÇ M, GÜRMAN G, Ilhan O, Konuk N, et al.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31

## **Metrics**

Publication: 380

Citation (WoS): 4704

Citation (Scopus): 5397

H-Index (WoS): 37

H-Index (Scopus): 41